Cargando…
Liposomal Resiquimod for Enhanced Immunotherapy of Peritoneal Metastases of Colorectal Cancer
Colorectal cancer with peritoneal metastases is currently treated by cytoreductive surgery and locoregional chemotherapeutics. This standard treatment is associated with high morbidity, mortality, and recurrence rate. To augment the existing therapy, we developed a liposome-based delivery system con...
Autores principales: | Pauli, Griffin, Chao, Po-Han, Qin, Zhu, Böttger, Roland, Lee, Suen Ern, Li, Shyh-Dar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540734/ https://www.ncbi.nlm.nih.gov/pubmed/34683992 http://dx.doi.org/10.3390/pharmaceutics13101696 |
Ejemplares similares
-
Development and Characterization of the Solvent-Assisted Active Loading Technology (SALT) for Liposomal Loading of Poorly Water-Soluble Compounds
por: Pauli, Griffin, et al.
Publicado: (2019) -
A Squalene-Based Nanoemulsion for Therapeutic Delivery of Resiquimod
por: Zhang, Zhongkun, et al.
Publicado: (2021) -
Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken
por: Matoo, Javaid Jeelani, et al.
Publicado: (2018) -
Resiquimod-Mediated Activation of Plasmacytoid Dendritic Cells Is Amplified in Multiple Sclerosis
por: Corsetti, Marta, et al.
Publicado: (2019) -
Comparing the immunogenicity of glycosidase-directed resiquimod prodrugs mediated by cancer cell metabolism
por: Ryan, Austin T, et al.
Publicado: (2020)